Zurcher Kantonalbank Zurich Cantonalbank Acquires 1,314 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Blueprint Medicines Co. (NASDAQ:BPMC) by 10.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 13,369 shares of the biotechnology company’s stock after acquiring an additional 1,314 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Blueprint Medicines were worth $1,233,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. SG Americas Securities LLC lifted its stake in Blueprint Medicines by 1,436.4% during the 3rd quarter. SG Americas Securities LLC now owns 33,478 shares of the biotechnology company’s stock valued at $1,681,000 after acquiring an additional 31,299 shares in the last quarter. Peregrine Capital Management LLC boosted its holdings in Blueprint Medicines by 2.1% during the third quarter. Peregrine Capital Management LLC now owns 146,663 shares of the biotechnology company’s stock worth $7,365,000 after purchasing an additional 3,074 shares during the last quarter. Harbor Capital Advisors Inc. grew its position in Blueprint Medicines by 33.4% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 32,484 shares of the biotechnology company’s stock worth $1,631,000 after purchasing an additional 8,131 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Blueprint Medicines by 1.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 266,744 shares of the biotechnology company’s stock valued at $13,396,000 after buying an additional 4,127 shares during the last quarter. Finally, Brown Advisory Inc. lifted its position in shares of Blueprint Medicines by 0.9% during the 3rd quarter. Brown Advisory Inc. now owns 641,039 shares of the biotechnology company’s stock worth $32,193,000 after buying an additional 5,843 shares in the last quarter.

Blueprint Medicines Stock Up 2.5 %

Blueprint Medicines stock opened at $93.00 on Friday. The firm has a 50 day simple moving average of $90.79 and a 200 day simple moving average of $78.80. The company has a current ratio of 3.76, a quick ratio of 3.66 and a debt-to-equity ratio of 1.60. Blueprint Medicines Co. has a 1-year low of $43.89 and a 1-year high of $101.00. The firm has a market capitalization of $5.69 billion, a price-to-earnings ratio of -11.12 and a beta of 0.63.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share for the quarter, beating the consensus estimate of ($2.04) by $0.22. The company had revenue of $71.96 million during the quarter, compared to analysts’ expectations of $67.34 million. Blueprint Medicines had a negative return on equity of 191.56% and a negative net margin of 203.30%. The firm’s quarterly revenue was up 85.5% compared to the same quarter last year. During the same period in the previous year, the business earned ($2.65) earnings per share. On average, analysts predict that Blueprint Medicines Co. will post -5.41 earnings per share for the current year.

Insider Activity

In related news, insider Christopher K. Murray sold 621 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $93.65, for a total transaction of $58,156.65. Following the sale, the insider now owns 36,374 shares of the company’s stock, valued at approximately $3,406,425.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Christopher K. Murray sold 621 shares of the business’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $93.65, for a total transaction of $58,156.65. Following the completion of the transaction, the insider now directly owns 36,374 shares in the company, valued at $3,406,425.10. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Michael Landsittel sold 5,000 shares of the firm’s stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $95.00, for a total value of $475,000.00. Following the completion of the sale, the chief financial officer now directly owns 47,286 shares in the company, valued at approximately $4,492,170. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 92,289 shares of company stock worth $8,314,163. 3.88% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages recently commented on BPMC. HC Wainwright reaffirmed a “buy” rating and set a $125.00 price target on shares of Blueprint Medicines in a research report on Friday. JMP Securities restated a “market outperform” rating and issued a $114.00 price objective on shares of Blueprint Medicines in a research note on Wednesday, April 10th. Citigroup lifted their target price on Blueprint Medicines from $54.00 to $65.00 and gave the stock a “sell” rating in a research note on Friday, February 16th. Barclays increased their price target on shares of Blueprint Medicines from $58.00 to $70.00 and gave the company an “equal weight” rating in a research report on Tuesday, February 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $97.00 price objective on shares of Blueprint Medicines in a research report on Friday. Four equities research analysts have rated the stock with a sell rating, two have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $91.57.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.